Effect of pidotimod on immunologic functions and clinical curative efficacy for patients undergoing recurrent respiratory tract infections
10.7501/j.issn.1674-6376.2016.05.018
- VernacularTitle:匹多莫德对反复呼吸道感染患儿免疫功能及临床疗效的影响
- Author:
Qinghua LUO
;
Yulan KANG
- Keywords:
pidotimod;
immunologic function;
recurrent respiratory tract infection;
children
- From:
Drug Evaluation Research
2017;40(5):679-682
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of pidotimod combined with antibacterials on the immunologic functions and clinical curative efficacy for patients undergoing recurrent respiratory tract infections.Methods Patients with recurrent respiratory tract infections (150 cases) were enrolled in Matemal and Child Health Hospital of Guangyuan from August 2013 to January 2016,which divided to two groups randomly,Group A (n =75) accepted traditional antibacterials treatment,and Group B (n =75) adopted pidotimod combined with antibacterials.The clinical symptom and immunologic functions of patients during treatment were tested,and the clinical curative efficacy of patients was evaluated in the follow-up period.Results After treatment,the disappear time of cough,fever,tonsil inflammation and pulmonary wheezing in treatment group was significantly shorter than that of control group (P ＜ 0.05).After treatment,the levels of serum immunoglobulin in two groups were higher than those before treatment (P ＜ 0.05),and the treatment group was significantly higher than control group (P ＜ 0.05).After treatment,the relative activities of CD3+,CD4+,CD8+,and NK cells in two groups increased significantly (P ＜ 0.05),the relative content of CD4+/CD8+ was also increased (P ＜0.05),and the improvement of above indexes in the treatment group was more obvious than those in control group (P ＜ 0.05).After treatment,total effective rate of treatment group was significantly higher than that of control group (P ＜ 0.05),the recurrence of infection in the treatment group is significantly lower than that in the control group (P ＜ 0.05),and the recurrence duration was significantly shorter than control group (P ＜ 0.05).Conclusion The clinical curative of pidotimod combined with antibacterials was remarkable for patients of recurrent respiratory tract infections,which deserved popularization not only improving the immunologic functions,but also decreasing the times of recurrence.
